Stay updated on Cabozantinib in RAI-Refractory DTC Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib in RAI-Refractory DTC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib in RAI-Refractory DTC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0. The page still displays a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-11-02T16:13:02.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    A site-wide NIH notice appears above the unavailable study record, announcing updates and FAQs about a terminology transition from “Artificial Intelligence” to “Super Intelligence.”
    Difference
    1%
    Check dated 2026-10-26T14:42:52.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The footer’s site revision label changed from v3.7.1 to v3.7.2 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-19T14:19:55.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-12T15:00:25.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The study record page now displays a 403 Forbidden message with a Home link instead of its usual study content.
    Difference
    0.5%
    Check dated 2026-10-05T17:18:17.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    The page now renders a 403 Forbidden error page with the standard header/footer and revision notice, replacing the expected study details.
    Difference
    16%
    Check dated 2026-09-21T22:24:19.000Z thumbnail image

Stay in the know with updates to Cabozantinib in RAI-Refractory DTC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib in RAI-Refractory DTC Clinical Trial page.